Pazopanib Maintenance Phase II

Summary

This trial compares pazopanib to placebo as maintenance treatment over 2 years in patients with retroperitoneal and visceral high-risk soft tissue sarcomas after multimodal treatment including prior neo- and/or adjuvant doxorubicin / ifosfamide chemotherapy with regional hyperthermia.

Timeline

Start

2015-06-22

Primary completion

2016-07-29

Completion

2016-07-29

Drugs

Indications